RAIS-DR系统提升糖尿病视网膜病变筛查准确率与公平性，适合临床落地。

Diabetic Retinopathy (DR) is a leading cause of vision loss in working-age individuals. Early detection of DR can reduce the risk of vision loss by up to 95%, but a shortage of retinologists and challenges in timely examination complicate detection. Artificial Intelligence (AI) models using retinal fundus photographs (RFPs) offer a promising solution. However, adoption in clinical settings is hindered by low-quality data and biases that may lead AI systems to learn unintended features. To address these challenges, we developed RAIS-DR, a Responsible AI System for DR screening that incorporates ethical principles across the AI lifecycle. RAIS-DR integrates efficient convolutional models for preprocessing, quality assessment, and three specialized DR classification models. We evaluated RAIS-DR against the FDA-approved EyeArt system on a local dataset of 1,046 patients, unseen by both systems. RAIS-DR demonstrated significant improvements, with F1 scores increasing by 5-12%, accuracy by 6-19%, and specificity by 10-20%. Additionally, fairness metrics such as Disparate Impact and Equal Opportunity Difference indicated equitable performance across demographic subgroups, underscoring RAIS-DR's potential to reduce healthcare disparities. These results highlight RAIS-DR as a robust and ethically aligned solution for DR screening in clinical settings. The code, weights of RAIS-DR are available at https://gitlab.com/inteligencia-gubernamental-jalisco/jalisco-retinopathy with RAIL.